Company intelligence / Profile preview

ALK-Abelló

Hørsholm, Denmarkalk.net ↗

Ownership: Private
Employees: ~2900
Development stage: Commercial

Overview

ALK has multiple approved products on the market including ACARIZAX/ODACTRA for house dust mite allergy, which recently received approval for use in children in Canada and the US. The company also has GRAZAX/GRASTEK for grass pollen allergy and other immunotherapy products.

Therapeutic areas: PulmonologyImmunology
Modalities: Allergy immunotherapy tabletssublingual or drop-based vaccinessubcutaneous vaccinesadrenaline auto-injectors
Industry: Biotech

Drug pipeline

187 assets

Dermatophagoides pteronyssinus allergoid

Approved

186 more assets in the full pipeline.

Request access →

Partnerships

Torii (Japan)

Beyond the preview

Go deeper on ALK-Abelló.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALK-Abelló.

Explore the full profile